2025
MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [18F] AV45 and FDG PET Imaging
saberian P, Darvishi A, khezragha D, Forouzandegan M, Farhadieh M, Khorshidi S, Nejad M, Sedighi S, Barati R, Safavi S, Sadeghi M, Gulisashvili D, Mayeli M, Shakeri S. MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [18F] AV45 and FDG PET Imaging. Brain And Behavior 2025, 15: e70572. PMID: 40418688, PMCID: PMC12105656, DOI: 10.1002/brb3.70572.Peer-Reviewed Original ResearchConceptsMiR-210-3pMiR-223-3p levelsMiR-423-5pMiR-660-5pMicroRNA levelsLet-7g-5pMiR-660MiR-423MiR-210Potential of microRNAsMiR-223Alzheimer's Disease Neuroimaging InitiativeMicroRNAsAlzheimer's diseaseAD continuumPotential biomarkersFindings of increased levelsCognitive declinePositron emission tomographyAPOE-e4 carriersAD groupAPOE-e4Cerebrospinal fluid levelsReuptakeBiomarkers of AD
2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud FG, Iorio MV, Verderio P, Daidone MG. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. International Journal Of Molecular Sciences 2020, 21: 1386. PMID: 32085669, PMCID: PMC7073028, DOI: 10.3390/ijms21041386.Peer-Reviewed Original ResearchConceptsPathological complete responseNeoadjuvant therapyHER2-positive breast cancer patientsTrastuzumab-based neoadjuvant therapyAvailable predictive biomarkersBreast cancer patientsEstrogen receptor statusComplete responseReceptor statusCancer patientsPredictive biomarkersTreatment responseHCC progressionPatientsPredictive valueBivariate analysisMean differencePlasma pairsTherapyEarly modulationMicroRNA levelsTrastuzumabMAPK signalingMetabolism regulationKEGG analysis
2016
Adenosine-to-inosine RNA editing by ADAR1 is essential for normal murine erythropoiesis
Liddicoat BJ, Hartner JC, Piskol R, Ramaswami G, Chalk AM, Kingsley PD, Sankaran VG, Wall M, Purton LE, Seeburg PH, Palis J, Orkin SH, Lu J, Li JB, Walkley CR. Adenosine-to-inosine RNA editing by ADAR1 is essential for normal murine erythropoiesis. Experimental Hematology 2016, 44: 947-963. PMID: 27373493, PMCID: PMC5035604, DOI: 10.1016/j.exphem.2016.06.250.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAdenosine DeaminaseAnimalsCluster AnalysisErythrocyte IndicesErythroid CellsErythropoiesisGene ExpressionGene Expression ProfilingGene Expression Regulation, DevelopmentalGene Knockout TechniquesGranulocytesHematopoietic Stem Cell TransplantationInosineInterferonsMiceMicroRNAsMyelopoiesisOrgan SpecificityPhenotypeReceptors, InterferonRetroelementsRNA EditingRNA-Binding ProteinsSignal TransductionTranscription, GeneticConceptsRNA editingErythroid cellsNormal erythropoiesisHematopoietic stem/progenitorsHematopoietic cell typesInnate immune signalingStem/progenitorsEditing eventsErythroid-specific transcriptsEssential functionsImmune signalingMurine erythropoiesisADAR1Cell deathCell typesMyeloid-restricted deletionEditingRNAMicroRNA levelsErythropoiesisCellsProfound activationTranscriptsSignalingAdenosine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply